Acadia Pharmaceuticals faced a significant setback as its Phase 3 schizophrenia drug, Pimavanserin, failed to demonstrate a statistically significant improvement over placebo on the study's primary endpoint, marking it as an efficacy failure. This failure, compounded by concerns over a 'lame safety slide,' has led to the decision to halt further testing of Nuplazid for schizophrenia, a drug currently approved for treating hallucinations associated with Parkinson’s disease psychosis in a late-stage clinical trial. Following the announcement of the trial's outcome, Acadia Pharma's stock fell by 15%. The company has faced years of failed efforts to expand Nuplazid's applications beyond its current approval.
Phase 3 Club 🧼Acadia Pharmaceuticals $ACAD hitting a major setback! Their phase 3 schizophrenia drug couldn't even beat out a placebo 🤯 They're scrapping the whole project. @MXLESQ Reminds me why I steer clear of those clinical trial stocks binary bets" Rebel's Edge🏴☠️ 1pm… https://t.co/q9EvdxvnHD
Acadia to end Nuplazid testing after schizophrenia trial flop and years of failed expansion efforts https://t.co/05XoaDQV5H
$GLSI is up 15% on getting closer to getting trial sites online in Spain. As if the trial is ever going to be positive anyway. A reminder of their prior data: https://t.co/WaR0JqcUVw
Currently approved to treat hallucinations associated with Parkinson’s disease psychosis, the drug failed to do better than placebo in a late-stage clinical trial. https://t.co/Llb1ll8tVx
Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study https://t.co/CJgTKGkyZv
Acadia Pharma’s stock falls 15% after failed drug trial https://t.co/mhyOiSgVRV
$ACAD Study fail: Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint. Major holders below: https://t.co/cG5Ylxubg5
$ACAD Study fail: Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint
$ACAD study failed. https://t.co/6dxywUrfJn
$ACAD halted, assuming ph3 schizophrenia readout
These $APLT govorestat SORD study results disclosed via an 8K this morning don't look great. Interim look but an efficacy failure? Wonky stats. Also, lame safety slide. h/t @AF2Communicate https://t.co/VRi6d6VhqF https://t.co/lQdgoHbSdl
So yes, $APLT failed that SORD deficiency study, just releasing some data via 8-K. Wasn't even close. https://t.co/IkUtXEvSBW https://t.co/sEyQUbJ8Fw